Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder
BackgroundBenzodiazepine (BZD) misuse is a significant public health problem, particularly in conjunction with opioid use, due to increased risks of overdose and death. One putative mechanism underlying BZD misuse is affective dysregulation, via exaggerated negative affect (e.g., anxiety, depression...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1103739/full |
| _version_ | 1797948137732571136 |
|---|---|
| author | Mark K. Greenwald Tabitha E. H. Moses Leslie H. Lundahl Timothy A. Roehrs Timothy A. Roehrs |
| author_facet | Mark K. Greenwald Tabitha E. H. Moses Leslie H. Lundahl Timothy A. Roehrs Timothy A. Roehrs |
| author_sort | Mark K. Greenwald |
| collection | DOAJ |
| description | BackgroundBenzodiazepine (BZD) misuse is a significant public health problem, particularly in conjunction with opioid use, due to increased risks of overdose and death. One putative mechanism underlying BZD misuse is affective dysregulation, via exaggerated negative affect (e.g., anxiety, depression, stress-reactivity) and/or impaired positive affect (anhedonia). Similar to other misused substances, BZD consumption is sensitive to price and individual differences. Although purchase tasks and demand curve analysis can shed light on determinants of substance use, few studies have examined BZD demand, nor factors related to demand.MethodsThis ongoing study is examining simulated economic demand for alprazolam (among BZD lifetime misusers based on self-report and DSM-5 diagnosis; n = 23 total; 14 male, 9 female) and each participant’s preferred-opioid/route using hypothetical purchase tasks among patients with opioid use disorder (n = 59 total; 38 male, 21 female) who are not clinically stable, i.e., defined as being early in treatment or in treatment longer but with recent substance use. Aims are to determine whether: (1) BZD misusers differ from never-misusers on preferred-opioid economic demand, affective dysregulation (using questionnaire and performance measures), insomnia/behavioral alertness, psychiatric diagnoses or medications, or urinalysis results; and (2) alprazolam demand among BZD misusers is related to affective dysregulation or other measures.ResultsLifetime BZD misuse is significantly (p < 0.05) related to current major depressive disorder diagnosis, opioid-negative and methadone-negative urinalysis, higher trait anxiety, greater self-reported affective dysregulation, and younger age, but not preferred-opioid demand or insomnia/behavioral alertness. Alprazolam and opioid demand are each significantly positively related to higher anhedonia and, to a lesser extent, depression symptoms but no other measures of negative-affective dysregulation, psychiatric conditions or medications (including opioid agonist therapy or inpatient/outpatient treatment modality), or sleep-related problems.ConclusionAnhedonia (positive-affective deficit) robustly predicted increased BZD and opioid demand; these factors could modulate treatment response. Routine assessment and effective treatment of anhedonia in populations with concurrent opioid and sedative use disorder may improve treatment outcomes.Clinical trial registrationhttps://clinicaltrials.gov/ct2/show/NCT03696017, identifier NCT03696017. |
| first_indexed | 2024-04-10T21:39:46Z |
| format | Article |
| id | doaj.art-ece647d24277446eb5a05d30769dfdaf |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-04-10T21:39:46Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-ece647d24277446eb5a05d30769dfdaf2023-01-19T07:33:22ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402023-01-011410.3389/fpsyt.2023.11037391103739Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorderMark K. Greenwald0Tabitha E. H. Moses1Leslie H. Lundahl2Timothy A. Roehrs3Timothy A. Roehrs4Substance Abuse Research Division, Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, MI, United StatesSubstance Abuse Research Division, Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, MI, United StatesSubstance Abuse Research Division, Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, MI, United StatesSubstance Abuse Research Division, Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, MI, United StatesSleep Disorders Center, Henry Ford Health System, Detroit, MI, United StatesBackgroundBenzodiazepine (BZD) misuse is a significant public health problem, particularly in conjunction with opioid use, due to increased risks of overdose and death. One putative mechanism underlying BZD misuse is affective dysregulation, via exaggerated negative affect (e.g., anxiety, depression, stress-reactivity) and/or impaired positive affect (anhedonia). Similar to other misused substances, BZD consumption is sensitive to price and individual differences. Although purchase tasks and demand curve analysis can shed light on determinants of substance use, few studies have examined BZD demand, nor factors related to demand.MethodsThis ongoing study is examining simulated economic demand for alprazolam (among BZD lifetime misusers based on self-report and DSM-5 diagnosis; n = 23 total; 14 male, 9 female) and each participant’s preferred-opioid/route using hypothetical purchase tasks among patients with opioid use disorder (n = 59 total; 38 male, 21 female) who are not clinically stable, i.e., defined as being early in treatment or in treatment longer but with recent substance use. Aims are to determine whether: (1) BZD misusers differ from never-misusers on preferred-opioid economic demand, affective dysregulation (using questionnaire and performance measures), insomnia/behavioral alertness, psychiatric diagnoses or medications, or urinalysis results; and (2) alprazolam demand among BZD misusers is related to affective dysregulation or other measures.ResultsLifetime BZD misuse is significantly (p < 0.05) related to current major depressive disorder diagnosis, opioid-negative and methadone-negative urinalysis, higher trait anxiety, greater self-reported affective dysregulation, and younger age, but not preferred-opioid demand or insomnia/behavioral alertness. Alprazolam and opioid demand are each significantly positively related to higher anhedonia and, to a lesser extent, depression symptoms but no other measures of negative-affective dysregulation, psychiatric conditions or medications (including opioid agonist therapy or inpatient/outpatient treatment modality), or sleep-related problems.ConclusionAnhedonia (positive-affective deficit) robustly predicted increased BZD and opioid demand; these factors could modulate treatment response. Routine assessment and effective treatment of anhedonia in populations with concurrent opioid and sedative use disorder may improve treatment outcomes.Clinical trial registrationhttps://clinicaltrials.gov/ct2/show/NCT03696017, identifier NCT03696017.https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1103739/fullbenzodiazepinedemandanhedoniaaffective dysregulationopioid use disorder |
| spellingShingle | Mark K. Greenwald Tabitha E. H. Moses Leslie H. Lundahl Timothy A. Roehrs Timothy A. Roehrs Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder Frontiers in Psychiatry benzodiazepine demand anhedonia affective dysregulation opioid use disorder |
| title | Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder |
| title_full | Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder |
| title_fullStr | Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder |
| title_full_unstemmed | Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder |
| title_short | Anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder |
| title_sort | anhedonia modulates benzodiazepine and opioid demand among persons in treatment for opioid use disorder |
| topic | benzodiazepine demand anhedonia affective dysregulation opioid use disorder |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1103739/full |
| work_keys_str_mv | AT markkgreenwald anhedoniamodulatesbenzodiazepineandopioiddemandamongpersonsintreatmentforopioidusedisorder AT tabithaehmoses anhedoniamodulatesbenzodiazepineandopioiddemandamongpersonsintreatmentforopioidusedisorder AT lesliehlundahl anhedoniamodulatesbenzodiazepineandopioiddemandamongpersonsintreatmentforopioidusedisorder AT timothyaroehrs anhedoniamodulatesbenzodiazepineandopioiddemandamongpersonsintreatmentforopioidusedisorder AT timothyaroehrs anhedoniamodulatesbenzodiazepineandopioiddemandamongpersonsintreatmentforopioidusedisorder |